Physician profile
James Clyde Lamon
NPI 1013019033
$8,504.27
in general payments reported to CMS, 2019-2025
43 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $1,118 · 2021: $1,385 · 2022: $1,593 · 2023: $1,556 · 2024: $999 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Gift: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,752.38 |
| Gift | $695.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,194.60 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Sekisui Diagnostics LLC | $960.00 | 2022-2025 | |
| Amgen INC. | $881.91 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $877.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $871.67 | 2019-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $545.56 | 2022-2025 | |
| Abbvie INC. | $373.40 | 2020-2025 | |
| Daiichi Sankyo INC. | $228.64 | 2019-2023 | Injectafer |
| Pfizer INC. | $215.44 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $208.18 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $169.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.32 | 2019-2020 | |
| Lilly USA, LLC | $143.88 | 2019-2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.61 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $137.89 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.